Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches

Bibliography

• Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 2007;19:397-417
   PubMed Web of Science ®Google Scholar
• Oehler C, Dickinson DJ, Broggini-Tenzer A, et al. Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. Curr Pharm Des 2007;13:519-35
   PubMed Web of Science ®Google Scholar
• Bischoff P, Altmeyer A, Dumont F. Radiosensitizing agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitizers. Expert Opin Ther Patents 2009;19(5):643-662
   Web of Science ®Google Scholar
• Jeggo P, Löbrich M. Radiation-induced DNA damage responses. Radiat Prot Dosimetry 2006;122:124-7
   PubMed Web of Science ®Google Scholar
• O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007;26:7816-24
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204
   PubMed Web of Science ®Google Scholar
• Cann KL, Hicks GG. Regulation of the cellular DNA double-strand break response. Biochem Cell Biol 2007;85:663-74
   PubMed Web of Science ®Google Scholar
• Kudos Pharmaceuticals Ltd. Aminopyrones and their use as ATM inhibitors. WO2005016919; 2005
   Google Scholar
• Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9
   PubMed Web of Science ®Google Scholar
• Cowell IG, Durkacz BW, Tilby MJ. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectasia mutated. Biochem Pharmacol 2005;71:13-20
   PubMed Web of Science ®Google Scholar
• Rainey MD, Charlton ME, Stanton RV, et al. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008;68:7466-74
   PubMed Web of Science ®Google Scholar
• Kudos Pharmaceuticals Ltd. ATM inhibitor. WO2007026157; 2007
   Google Scholar
• Southern Research Institute. Targeting NBS1-ATM interaction to sensitize cancer cells to radiotherapy and chemotherapy. WO2008054726; 2008
   Google Scholar
• Shinohara ET, Geng L, Tan J, et al. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 2005;65:4987-92
   PubMed Web of Science ®Google Scholar
• Kudos Pharmaceuticals Ltd, Cancer Rec Tech Ltd. DNA-PK inhibitors. WO2006109081; 2006
   Google Scholar
• Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66:5354-62
   PubMed Web of Science ®Google Scholar
• Albertella MR, Slade A, Shea KF, et al. Potent in vitro and in vivo radiosensitisation by the selective DNA-dependent protein kinase inhibitor KU-0060648 [abstract 4080]. Proc Am Assoc Cancer Res 2008;49
   Google Scholar
• Kudos Pharmaceuticals Ltd, Cancer Rec Tech Ltd. Use of DNA-PK inhibition to sensitise ATM-deficient cancers to DNA-damaging cancer therapies. WO2006126010; 2006
   Google Scholar
• Institut Curie, Centre National de la Recherche Scientifique. Dbait and uses thereof. WO2008034866; 2008
   Google Scholar
• Quanz M, Berthault N, Roulin C, et al. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. Clin Cancer Res 2009;15:1308-16
   PubMed Web of Science ®Google Scholar
• Beretta GL, Gatti L, Benedetti V, et al. Small molecules targeting p53 to improve antitumor therapy. Mini Rev Med Chem 2008;8:856-68
   PubMed Web of Science ®Google Scholar
• Janetka JW, Ashwell S, Zabludoff S, et al. Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Dev 2007;10:473-86
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Urea derivatives as kinase inhibitors. EP1534692; 2005
   Google Scholar
• Chen Z, Xiao Z, Gu WZ, et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 2006;119:2784-94
   PubMed Web of Science ®Google Scholar
• Chiron Corporation. Combination therapy with CHK1 inhibitors. US2005256157; 2005
   Google Scholar
• Tao Y, Leteur C, Yang C, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: Effects of p53 and cell cycle checkpoints. Cell Cycle 2009;8:1196-205
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Aminopyrazole compounds and use as Chk1 inhibitors. WO2005009435; 2005
   Google Scholar
• Cullinane C, Raleigh J, Anderes K, et al. Mechanisms of radiation enhancement by the CHK1 inhibitor PF-477736 [abstract 5386]. Proc Am Assoc Cancer Res 2007;48
   Google Scholar
• Clinical Trials. Available from: www.clinicaltrials.gov.
   Google Scholar
• Wu W, Wang M, Wu W, et al. Repair of radiation induced DNA double strand breaks by backup NHEJ is enhanced in G2. DNA Repair 2008;7:329-38
   PubMed Web of Science ®Google Scholar
• Weltin D, Holl V, Hyun JW, et al. Effect of 6(5H)-phenanthridinone, a poly (ADP-ribose) polymerase inhibitor, and ionizing radiation on the growth of cultured lymphoma cells. Int J Radiat Biol 1997;72:685-92
   PubMed Web of Science ®Google Scholar
• Chalmers AJ. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. Clin Oncol (R Coll Radiol) 2004;16:29-39
   PubMed Web of Science ®Google Scholar
• Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-8
   PubMed Web of Science ®Google Scholar
• Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67
   PubMed Web of Science ®Google Scholar
• Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945-56
   PubMed Web of Science ®Google Scholar
• Pfizer, Cancer Research Technology Ltd. Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor. WO2006033006; 2006
   Google Scholar
• Abbott Laboratories. 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors. WO2006110816; 2006
   Google Scholar
• Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37
   PubMed Web of Science ®Google Scholar
• Liu SK, Coackley C, Krause M, et al. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008;88:258-68
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Combination therapy with PARP inhibitors. WO2007084532; 2007
   Google Scholar
• MGI GP Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP. US2008058325; 2008
   Google Scholar
• Russo AL, Kwon HC, Burgan WE, et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009;15:607-12
   PubMed Web of Science ®Google Scholar
• Cephalon Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent. WO2008063644; 2008
   Google Scholar
• Burd R, Limesand K, Lavorgna S, et al. The selective PARP inhibitor, CEP-9722, exhibits significant radiosensitization against radioresistant U87 human glioblastoma xenografts and does not potentiate radiation-induced normal tissue toxicity [abstract 42114]. Proc Am Assoc Cancer Res 2008;49
   Google Scholar
• Bianco R, Gelardi T, Damiano V, et al. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007;39:1416-31
   PubMed Web of Science ®Google Scholar
• Valerie K, Yacoub A, Hagan MP, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007;6:789-801
   PubMed Web of Science ®Google Scholar
• Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007;13:6555-60
   PubMed Web of Science ®Google Scholar
• Rodemann HP, Dittmann K, Toulany M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 2007;83:781-91
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Dikomey E, et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 2007;83:238-48
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
   PubMed Web of Science ®Google Scholar
• Harari PM, Chinnaiyan P. Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor. WO2006110176; 2006
   Google Scholar
• Magné N, Chargari C, Castadot P, et al. The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. Eur J Cancer 2008;44:2133-43
   PubMed Web of Science ®Google Scholar
• Piperdi B. Combined treatment with bortezomib and an epidermal growth factor receptor inhibitor. WO2006110175; 2006
   Google Scholar
• LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008;11:32-50
   PubMed Web of Science ®Google Scholar
• OSI Pharmaceuticals Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors. WO2007106503; 2007
   Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Int, Boehringer Ingelheim Pharmaceuticals. Combination treatment of cancer comprising EGFR/HER2 inhibitors. WO2007054551; 2007
   Google Scholar
• Schütze C, Dörfler A, Eicheler W, et al. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 2007;183:256-64
   PubMed Web of Science ®Google Scholar
• Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008;9:288-96
   PubMed Web of Science ®Google Scholar
• Prolx Pharmaceuticals Corp, University of Arizona, University of Pittsburgh. Wortmannin analogs and methods of using same in combination with chemotherapeutic agents. WO2007008200; 2007
   Google Scholar
• Hayakawa M, Kaizawa H, Morimoto H, et al. Fused heterolaryl derivatives. US7173029; 2007
   Google Scholar
• Prevo R, Deutsch E, Sampson O, et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008;68:5915-23
   PubMed Web of Science ®Google Scholar
• Chen JS, Zhou LJ, Entin-Meer M, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther 2008;7:841-50
   PubMed Web of Science ®Google Scholar
• Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009;8:1-9
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Iwado E, Mills GB, et al. Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol 2007;31:753-60
   PubMed Web of Science ®Google Scholar
• Toulany M, Kehlbach R, Florczak U, et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 2008;7:1772-81
   PubMed Web of Science ®Google Scholar
• Paloma Pharmaceuticals, Inc. Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis. WO2007133249; 2007
   Google Scholar
• Diaz R, Nguewa PA, Diaz-Gonzalez JA, et al. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br J Cancer 2009;100:932-40
   PubMed Web of Science ®Google Scholar
• Trustees of the University of Pennsylvania. The use of nelfinavir as a radiation sensitizer. WO2006044808; 2006
   Google Scholar
• Plastaras JP, Vapiwala N, Ahmed MS, et al. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther 2008;7:628-35
   PubMed Web of Science ®Google Scholar
• Albert JM, Kim KW, Cao C, et al. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006;5:1183-9
   PubMed Web of Science ®Google Scholar
• Murphy JD, Spalding AC, Somnay YR, et al. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res 2009;15:589-96
   PubMed Web of Science ®Google Scholar
• Ahmed KM, Li JJ. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 2008;44:1-13
   PubMed Web of Science ®Google Scholar
• Georgetown University. The p65 subunit of NF-KB for the radiosensitization of cells US2005287158; 2005
   Google Scholar
• University of California. DHMEQ as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells. WO2006060819; 2006
   Google Scholar
• Sun Y, St Clair DK, Fang F, et al. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 2007;6:2477-86
   PubMed Web of Science ®Google Scholar
• Tamatani T, Azuma M, Motegi K, et al. Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral squamous cell carcinoma cells. Int J Oncol 2007;31:761-8
   PubMed Web of Science ®Google Scholar
• Xu Y, Fang F, St Clair DK, et al. SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol Cancer Ther 2008;7:2367-76
   PubMed Web of Science ®Google Scholar
• Lee DF, Hung MC. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 2008;14:5656-62
   PubMed Web of Science ®Google Scholar
• Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008;9:1002-11
   PubMed Web of Science ®Google Scholar
• Aprea AB. 1-Azabicyclo [2,2,2] octan-3-one derivatives. US2005090540; 2005
   Google Scholar
• Supiot S, Zhao H, Wiman K, et al. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol 2008;86:407-11
   PubMed Web of Science ®Google Scholar
• Hoffmann La Roche. Novel cis-imidazolines. WO2005110996; 2005
   Google Scholar
• Cao C, Shinohara ET, Subhawong TK, et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther 2006;5:411-7
   PubMed Web of Science ®Google Scholar
• Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008;7:993-9
   PubMed Web of Science ®Google Scholar
• An J, Chervin AS, Nie A, et al. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 2007;26:652-61
   PubMed Web of Science ®Google Scholar
• University of Michigan, University of Georgetown Medical Center. Small molecule antagonists of Bcl-2 family proteins. WO2005069771; 2005
   Google Scholar
• Abbott Laboratories. Apoptosis promoters. WO2006127364; 2006
   Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81
   PubMed Web of Science ®Google Scholar
• AVI Biopharma Inc. Method and antisense compound for potentiating anti-cancer agents. WO2005047465; 2005
   Google Scholar
• Aegera Therapeutics Inc. Antisense IAP nucleobase oligomers and uses thereof. US7091333; 2006
   Google Scholar
• Giagkousiklidis S, Vellanki SH, Debatin KM, et al. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007;26:7006-16
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Nagata Y, Takahashi A, et al. Effective enhancement of X-ray-induced apoptosis in human cancer cells with mutated p53 by siRNA targeting XIAP. Oncol Rep 2008;20:57-61
   PubMed Web of Science ®Google Scholar
• University of Michigan. Smac peptidomimetics and uses thereof. WO2005069888; 2005
   Google Scholar
• University of Michigan. Conformationally constrained Smac mimetics and the uses thereof. WO2006010118; 2006
   Google Scholar
• Dai Y, Liu M, Tang W, et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res 2008;14:7701-10
   PubMed Web of Science ®Google Scholar
• Burnham Institute, Torrey Pines Institute for Molecular Studies. Methods and compositions for derepression of IAP-inhibited caspase. US20050119176; 2005
   Google Scholar
• Karikari CA, Roy I, Tryggestad E, et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007;6:957-66
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70
   PubMed Web of Science ®Google Scholar
• Capalbo G, Rödel C, Stauber RH, et al. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007;183:593-9
   PubMed Web of Science ®Google Scholar
• Isis Pharmaceuticals Inc, Eli Lilly Co. Modulation of survivin expression. WO2005002507; 2005
   Google Scholar
• Rödel F, Frey B, Leitmann W, et al. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008;71:247-55
   PubMed Web of Science ®Google Scholar
• Santaris Pharma AS. LNA oligonucleotides and the treatment of cancer. WO2006050732; 2006
   Google Scholar
• Yamanouchi Pharma Co Ltd. Fused imidazolium derivatives. US6734203; 2004
   Google Scholar
• Iwasa T, Okamoto I, Suzuki M, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008;14:6496-504
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-2
   PubMed Web of Science ®Google Scholar
• Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Invest Drugs 2007;16:659-78
   PubMed Web of Science ®Google Scholar
• Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007;25:4051-6
   PubMed Web of Science ®Google Scholar
• Georgetown University. Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy US2005222013; 2005
   Google Scholar
• Sloan Kettering Institute for Cancer Research. Combination therapy for the treatment of cancer. EP1501489; 2005
   Google Scholar
• Novartis Pharmaceuticals GMBH. Combination of histone deacetylase inhibitors and radiation. WO2007050655; 2007
   Google Scholar
• Geng L, Cuneo KC, Fu A, et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006;66:11298-304
   PubMed Web of Science ®Google Scholar
• Kim IA, Shin JH, Kim IH, et al. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 2006;12:940-9
   PubMed Web of Science ®Google Scholar
• Georgetown University. Isoform-selective HDAC inhibitors. WO2008019025; 2008
   Google Scholar
• Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007;13:1625-9
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-53
   PubMed Web of Science ®Google Scholar
• Camphausen K, Tofilon PJ. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 2007;13:4326-30
   PubMed Web of Science ®Google Scholar
• Van Andel Research Institute. Geldanamycin and derivatives inhibit cancer invasion and identify novel targets. WO2005095347; 2005
   Google Scholar
• Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009;17:2225-35
   PubMed Web of Science ®Google Scholar
• Sloan-Kettering Institute for Cancer Research. Small-molecule Hsp90 inhibitors. WO2006084030; 2006
   Google Scholar
• Patterson DM, Rustin GJ. Vascular damaging agents. Clin Oncol (R Coll Radiol) 2007;19:443-56
   PubMed Web of Science ®Google Scholar
• Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res 2008;100:113-31
   PubMed Web of Science ®Google Scholar
• Shannon AM, Williams KJ. Antiangiogenics and radiotherapy. J Pharm Pharmacol 2008;60:1029-36
   PubMed Web of Science ®Google Scholar
• Roskoski RJ. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179-213
   PubMed Web of Science ®Google Scholar
• Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007;26:281-90
   PubMed Web of Science ®Google Scholar
• Brieger J, Kattwinkel J, Berres M, et al. Impact of vascular endothelial growth factor release on radiation resistance. Oncol Rep 2007;18:1597-601
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals. Use of a VEGF antagonist in combination with radiation therapy. WO2005016369; 2005
   Google Scholar
• Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol Phys 2007;67:1526-37
   PubMed Web of Science ®Google Scholar
• Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007;13:3397-402
   Google Scholar
• Williams KJ, Telfer BA, Shannon AM, et al. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 2007;6:599-606
   PubMed Web of Science ®Google Scholar
• Astrazeneca AB. Combination of ZD6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer. EP1534287; 2005
   Google Scholar
• Shibuya K, Komaki R, Shintani T, et al. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;69:1534-43
   PubMed Web of Science ®Google Scholar
• Oehler-Jänne C, Jochum W, Riesterer O, et al. Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models. Mol Cancer Ther 2007;6:2496-504
   PubMed Web of Science ®Google Scholar
• Bozec A, Sudaka A, Fischel JL, et al. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008;99:93-9
   PubMed Web of Science ®Google Scholar
• Vanderbilt University. PI3K antagonists as radiosensitizers. US2006084697; 2006
   Google Scholar
• Toyo Suisan Kaisha. Radiosensitizer. EP1734046; 2006
   Google Scholar
• Sakimoto I, Ohta K, Yamazaki T, et al. Alpha-sulfoquinovosylmonoacyl-glycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Cancer Res 2006;66:2287-95
   PubMed Web of Science ®Google Scholar
• Mori Y, Sahara H, Matsumoto K, et al. Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3′-sulfoquinovosyl-1′-monoacylglycerol, targeting angiogenesis. Cancer Sci 2008;99:1063-70
   PubMed Web of Science ®Google Scholar
• University of Minnesota. Tumor treatment using beta-sheet peptides and radiotherapy. CA2528635; 2007
   Google Scholar
• Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006;103:15975-80
   PubMed Web of Science ®Google Scholar
• Dings RP, Williams BW, Song CW, et al. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 2005;115:312-9
   PubMed Web of Science ®Google Scholar
• National Institute of Radiological Sciences, Kringle Pharmaceuticals Inc. Radiotherapy enhancing agent in radiotherapy for tumor. WO2007091681; 2007
   Google Scholar
• Matsumoto K, Nakamura T, Sakai K, et al. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics 2008;8:3360-70
   PubMed Web of Science ®Google Scholar
• Uto Y, Nagasawa H, Jin CZ, et al. Design of antiangiogenic hypoxic cell radiosensitizers: 2-Nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety. Bioorg Med Chem 2008;16:6042-53
   PubMed Web of Science ®Google Scholar
• Bristow RG, Hill RP. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-92
   PubMed Web of Science ®Google Scholar
• Hamada N. Recent insights into the biological action of heavy-ion radiation. J Radiat Res (Tokyo) 2009;50:1-9
   PubMed Web of Science ®Google Scholar